经肝段动脉栓塞治疗中晚期肝癌

来源 :中国肿瘤临床 | 被引量 : 0次 | 上传用户:dulizhi123
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:探讨105例不能手术切除的中晚期肝癌经肝段动脉栓塞治疗效果和治疗成功的关键步骤。方法:通过肝动脉造影,对105例不能手术切除的中晚期肝癌经肿瘤供血的肝段动脉进行化疗栓塞治疗。结果:肝段动脉栓塞术者的1,2,3,4和5年的生存率分别为90.0%、70.0%、50.0%、40.0%和30.0%;肝动脉栓塞术后联合肝段动脉栓塞术者其1,2,3,4和5年生存率分别为74.5%、49.1%、40.0%、29.1%和20.0%。结论:肝段动脉栓塞术是最佳的治疗方式,肝动脉栓塞术联合肝段动脉栓塞术可显著提高不能手术切除的中晚期肝癌的生存率。 Objective: To investigate the treatment of 105 cases of unresectable advanced liver cancer by hepatic artery embolization and the key steps of success. Methods: Hepatic artery angiography was performed in 105 patients with unresectable advanced liver cancer treated by tumor embolization. Results: The 1, 2, 3, 4, and 5-year survival rates of hepatic artery embolization were 90.0%, 70.0%, 50.0%, 40.0% and 30.0% respectively. Liver The 1, 2, 3, 4 and 5-year survival rates of patients with arterial embolization and hepatic artery embolization were 74.5%, 49.1%, 40.0%, 29.1% and 20.0%, respectively . Conclusion: Hepatic artery embolization is the best treatment. Hepatic artery embolization combined with hepatic artery embolization can significantly improve the survival rate of unresectable advanced hepatocellular carcinoma.
其他文献
目的:比较诺维本持续静脉输注与常规用法治疗晚期非小细胞肺癌的疗效和毒性。方法:统计分析持续静脉输注和常规用法组治疗的49例晚期非小细胞肺癌病例的临床资料。结果:持续输注
#
期刊
#
恶心胸水是恶性肿瘤晚期较常见的并发症,尽管目前治疗恶性胸水的方案很多,包括局部与全身化疗,但所报道的结果并不一致。我科自1998年1月~1999年12月采用沈阳协合集团生产的高聚
介绍了一种用于高性能聚合物纺丝溶液过滤器的清洁工艺.采用FilaTech公司的标准TEG过滤设备,附加一道引入微量氧气真空热解处理工序,可以从烧结非织造不锈钢过滤介质上清除像
#
期刊
#
期刊
期刊
#
期刊
#
期刊
#
期刊
#